Market Cap 573.40M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 1,200,900
Avg Vol 1,794,018
Day's Range N/A - N/A
Shares Out 73.42M
Stochastic %K 36%
Beta 2.38
Analysts Strong Sell
Price Target $18.58

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
Nolanmp26
Nolanmp26 Sep. 12 at 12:09 PM
$ARVN. I’m a buyer break $7.85
0 · Reply
buyandsold
buyandsold Sep. 9 at 9:21 PM
$ARVN i think Pfizer will announce something overnight...
1 · Reply
G101SPM
G101SPM Sep. 9 at 3:00 PM
G101SPM 8/11/2025, 6:03:03 AM $ARVN $6.39 bid. DAC (dollar average cost) $7.75 (6.17.25). EXIT $12.00.
1 · Reply
buyandsold
buyandsold Sep. 7 at 8:10 PM
$ARVN vs. $PFE Vepdeg hardball is in the ninth innings. Pfizer is butt hurt after paying $650M for a second line therapy. Arvinas is angry trials were shut down that could have led to more than a 2nd line drug. They want to be done with each other, but if Pfizer buys Arvinas they will be forever united.
2 · Reply
buyandsold
buyandsold Sep. 5 at 4:55 PM
$ARVN Cantor worth a listen. Sounds like Pfizer and Arvinas will outlicense Vepdeg to a 3rd party
1 · Reply
zxbasyxbals
zxbasyxbals Sep. 4 at 7:50 PM
$ARVN It seems they cancelled their presentation today?
1 · Reply
buyandsold
buyandsold Sep. 4 at 1:35 PM
$ARVN Pfizer moving on from Vepdeg and Arvinas https://www.globenewswire.com/news-release/2025/09/02/3142485/0/en/Olema-Oncology-Announces-New-Clinical-Trial-Agreement-with-Pfizer-to-Combine-Palazestrant-with-Atirmociclib-in-ER-HER2-Metastatic-Breast-Cancer.html
2 · Reply
MadMusk
MadMusk Aug. 28 at 12:10 PM
$OTLK it’s Almost always lose/lose Situation after pdufa $VYNE $ARVN $ITRM $PLX
1 · Reply
buyandsold
buyandsold Aug. 27 at 10:08 PM
$ARVN i sent letters to the Board today. Expect action soon!
0 · Reply
biopuzzle
biopuzzle Aug. 27 at 7:46 PM
$ARVN Beautiful green candle 🟩
0 · Reply
Latest News on ARVN
Arvinas to Participate in Upcoming Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 15 days ago

Arvinas to Participate in Upcoming Investor Conferences


Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 5 weeks ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript


Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 3 months ago

Arvinas to Present at Jefferies Global Healthcare Conference


Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:40 PM EDT - 4 months ago

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript


Nolanmp26
Nolanmp26 Sep. 12 at 12:09 PM
$ARVN. I’m a buyer break $7.85
0 · Reply
buyandsold
buyandsold Sep. 9 at 9:21 PM
$ARVN i think Pfizer will announce something overnight...
1 · Reply
G101SPM
G101SPM Sep. 9 at 3:00 PM
G101SPM 8/11/2025, 6:03:03 AM $ARVN $6.39 bid. DAC (dollar average cost) $7.75 (6.17.25). EXIT $12.00.
1 · Reply
buyandsold
buyandsold Sep. 7 at 8:10 PM
$ARVN vs. $PFE Vepdeg hardball is in the ninth innings. Pfizer is butt hurt after paying $650M for a second line therapy. Arvinas is angry trials were shut down that could have led to more than a 2nd line drug. They want to be done with each other, but if Pfizer buys Arvinas they will be forever united.
2 · Reply
buyandsold
buyandsold Sep. 5 at 4:55 PM
$ARVN Cantor worth a listen. Sounds like Pfizer and Arvinas will outlicense Vepdeg to a 3rd party
1 · Reply
zxbasyxbals
zxbasyxbals Sep. 4 at 7:50 PM
$ARVN It seems they cancelled their presentation today?
1 · Reply
buyandsold
buyandsold Sep. 4 at 1:35 PM
$ARVN Pfizer moving on from Vepdeg and Arvinas https://www.globenewswire.com/news-release/2025/09/02/3142485/0/en/Olema-Oncology-Announces-New-Clinical-Trial-Agreement-with-Pfizer-to-Combine-Palazestrant-with-Atirmociclib-in-ER-HER2-Metastatic-Breast-Cancer.html
2 · Reply
MadMusk
MadMusk Aug. 28 at 12:10 PM
$OTLK it’s Almost always lose/lose Situation after pdufa $VYNE $ARVN $ITRM $PLX
1 · Reply
buyandsold
buyandsold Aug. 27 at 10:08 PM
$ARVN i sent letters to the Board today. Expect action soon!
0 · Reply
biopuzzle
biopuzzle Aug. 27 at 7:46 PM
$ARVN Beautiful green candle 🟩
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 9:00 AM
UBS has updated their rating for Arvinas ( $ARVN ) to Buy with a price target of 90.
1 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 9:00 AM
UBS has updated their rating for Arvinas ( $ARVN ) to Buy with a price target of 74.
0 · Reply
ccdemuth
ccdemuth Aug. 25 at 5:25 PM
$ARVN https://www.yetanothervalueblog.com/p/an-open-letter-to-the-arvn-board
1 · Reply
buyandsold
buyandsold Aug. 23 at 8:16 PM
$ARVN i think we could see $7.90 on Monday as the Logos letter highlights the value. Even if we can only get $5 dividend we'd be in great shape
1 · Reply
MomentumSpark
MomentumSpark Aug. 23 at 6:02 AM
$ARVN Arvinas Inc is a protein degradation company with promising oncology platform and partnerships
1 · Reply
buyandsold
buyandsold Aug. 23 at 12:48 AM
$ARVN Logos has politely requested a $9.60 dividend, a 5 for 1 reverse split, and a lean approach to the future. I approve this message.
0 · Reply
TwongStocks
TwongStocks Aug. 22 at 8:52 PM
$ARVN Logos Global Management filed a 13D. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000557/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 6.3m shares, 8.6%. Under Item 3, they disclosed buying 3,200,000 shares on the open market from May 1 - August 18 for a total purchase price of $23,534,011.75. Under Item 4, they disclosed some communication with the company: • Jun 10 they sent an email recommending a strategic reset of the company's direction and structure • Aug 7 they sent a letter to the board requesting (i) return $700 million of capital to stockholders, (ii) substantially reduce operating expenses and right-size the organization, (iii) allow the company's valuation to rebase around its core science, (iv) execute a 1-for-5 reverse stock split to facilitate institutional re-engagement, and (v) rebuild the company's credibility through disciplined capital allocation and business development.
1 · Reply
buyandsold
buyandsold Aug. 18 at 4:44 AM
$ARVN may just burn cash until Vepdeg approval. And then what? Cant imagine why they cant find a CEO.
1 · Reply
diegosan21
diegosan21 Aug. 15 at 8:21 PM
Strong week 🦾🦾🚀 $SRPT $APLS $AAL $ARVN
0 · Reply
diegosan21
diegosan21 Aug. 15 at 4:44 PM
$SRPT $APLS $ARVN looking great today
0 · Reply
sullivan_schwartz81
sullivan_schwartz81 Aug. 14 at 4:59 PM
$ARVN UTRX isn’t “exposed” to BTC… they’re LIVING in it Every sat mined = more LIQ, more deals, more upside 🚀 You think this stays a $3M mcap when BTC runs? LMAO.
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 14 at 2:13 PM
$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX
1 · Reply